Intervention Review

You have free access to this content

Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction

  1. Jodie M Dodd1,*,
  2. Anne McLeod2,
  3. Rory C Windrim3,
  4. John Kingdom3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 24 JUL 2013

Assessed as up-to-date: 24 OCT 2012

DOI: 10.1002/14651858.CD006780.pub3


How to Cite

Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD006780. DOI: 10.1002/14651858.CD006780.pub3.

Author Information

  1. 1

    The University of Adelaide, School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology, Adelaide, South Australia, Australia

  2. 2

    University of Toronto, Department of Medicine, Toronto, Canada

  3. 3

    University of Toronto, Department of Obstetrics and Gynaecology, Toronto, Canada

*Jodie M Dodd, School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide, South Australia, 5006, Australia. jodie.dodd@adelaide.edu.au.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 24 JUL 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Gris 2010 {published data only}
  • Gris JC, Chauleur C, Faillie JL, Baer G, Mares P, Fabbro-Peray P, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae: the pilot randomised controlled NOH-AP trial. Thrombosis and Haemostasis 2010; Vol. 104, issue 4:771-9.
Gris 2011 {published data only}
  • Gris JC, Chauleur C, Molinari N, Mares P, Fabbro-Peray P, Quere I, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: The pilot randomised controlled NOH-PE trial. Thrombosis and Haemostasis 2011;106(6):1053-61.
Kincaid-Smith 1995 {published data only}
  • Kincaid Smith P, North RA, Fairley KF, Kloss M, Ihle BU. Prevention of pre-eclampsia in high risk women with renal disease: a prospective randomized trial of heparin and dipyridamole. Nephrology 1995;1:297-300.
Kingdom 2011 {published data only}
  • Kingdom J D Current. Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction?. Controlled Trials (www.controlled-trials.com) (accessed 21 June 2007).
  • Kingdom JCP, Walker M, Proctor LK, Keating S, Shah PS, McLeod A, et al. Unfractionated heparin for second trimester placental insufficiency: A pilot randomized trial. Journal of Thrombosis and Haemostasis 2011;9(8):1483-92.
  • Walker M, Proctor L, Dodd J, Keunen H, Keating S, McLeod A, et al. Heparin to prevent placental insufficiency (HEPRIN): A pilot randomized controlled trial. Reproductive Sciences 2011;3(Suppl 1):361A-2A.
Martinelli 2012 {published data only}
  • Martinelli I. Low molecular weight heparin in pregnant women with previous obstetrical complications. A multicenter, randomized trial. Pathophysiology of Haemostasis and Thrombosis 2010;37 Suppl 1:A3.
  • Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: A prospective, randomized, multicenter, controlled clinical trial. Blood 2012;119(14):3269-75.
Mello 2005 {published data only}
  • Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al. Efficacy of LMWH in lowering the recurrence rate of preeclampsia and in restoring the physiological vascular changes in ACE DD genotype women [abstract]. Hypertension in Pregnancy 2004;23(Suppl 1):162.
  • Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005;45(1):86-91.
Nieder 1995 {published data only}
  • Nieder J, Claus P, Augustin W. Prevention of pre-eclampsia and fetal growth retardation by trapidil. Zentralblatt fur Gynakologie 1995;117:23-8.
Rey 2009 {published data only}
  • Rey E. Dalteparin in prevention of recurrence of severe obstetrical complications in women without thrombophilia. JOGC: Journal of Obstetrics and Gynaecology Canada 2007;29(6 Suppl 1):S46.
  • Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis 2009;7(1):58-64.
Yu 2004a {published data only}
  • Yu YH, Shen LY, Zhong M, Zhang Y, Su GD, Gao YF, et al. Effect of heparin on fetal growth restriction. Chung-Hua Fu Chan Ko Tsa Chih 2004;39(12):793-6.
Yu 2010 {published data only}
  • Yu YH, Shen LY, Zou H, Wang ZJ, Gong SP. Heparin for patients with growth restricted fetus: a prospective randomized controlled trial. Journal of Maternal-Fetal and Neonatal Medicine 2010;23(9):980-7.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Airoldi 1988 {published data only}
  • Airoldi ML, Capetta P, Tasca A, Bertulessi C, Rossi E, Polvani F. Role of early treatment with heparin and dipyridamole in the prevention of pre-eclampsia and placental insufficiency. 6th International Congress of the International Society for the Study of Hypertension in Pregnancy; 1988 May 22-26; Montreal, Quebec, Canada. 1988:233.
Eid 2006 {published data only}
  • Eid M, Taye A. Tinzaparin sodium supplementation improves the obstetric outcomes in singleton gestations following ART. Human Reproduction 2006;21(Suppl):i70.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Bonnar 1980 {published data only}
  • Bonnar J, Gitt BP. Prevention of fetal growth retardation by antithrombotic therapy. 2nd Congress of the International Society for the Study of Hypertension in Pregnancy; 1980 Dec 1-4; Cairo Egypt. 1980:60.
  • Gill BP, Bonnar J. Controlled study of subcutaneous heparin and dipyridamole in women at risk to fetal growth retardation. 1st Congress of the International Society of Hypertension in Pregnancy; 1978 September 27-29; Dublin, Ireland. 1978:97.
Ferrier 2000 {published data only}
  • Ferrier C, Koeferl U, Duerig P, Schneider H. Effects of LMW-heparin and low-dose aspirin on renal uric acid handling in high-risk pregnancies. Hypertension in Pregnancy 2000;19(Suppl 1):O68.
  • Ferrier C, Koferl U, Durig P, Schneider H. LMW-heparin and low-dose aspirin for prevention of preeclampsia: preliminary data of a randomized prospective study [abstract]. Hypertension in Pregnancy 2000;19(1):82.
Yu 2004b {published data only}
  • Yu YH, Shen LY, Wang ZJ, Zhang Y, Su GD. [Effect of heparin on umbilical blood flow in patients with fetal growth retardation]. [Chinese]. Di Yi Junyi Daxue Xuebao 2004; Vol. 24, issue 4:423-5.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Alkazaleh 2004
Bernstein 2000
  • Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A, for the Vermont Oxford Network. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. American Journal of Obstetrics and Gynecology 2000;182(1):198-206.
Bonnar 1975
  • Bonnar J, Redman CW, Sheppard BL. Treatment of fetal growth retardation in utero with heparin and dipyridamole. European Journal of Obstetrics & Gynecology and Reproductive Biology 1975;5(1-2):123-34.
Burton 2009
  • Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009;30(6):473-82.
Buyse 1974
  • Buyse FG, Wormgoor BH, Bernard JT, Koudstaal J. Anticoagulant therapy of patients with repeated placental infarction. Obstetrics & Gynecology 1974;43(6):844-8.
Chupin 1978
  • Chupin L, Herrmann JM, Maillet R, Gillet JY, Colette C, Gibey R, et al. The effects of heparin in underdevelopment of the fetus due to maternal vascular conditions. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction 1978;7(4):849-54.
Cnattingius 1998
  • Cnattingius S, Haglund B, Kramer MS. Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population based cohort study. BMJ 1998;316:1483-7.
Deeks 2001
  • Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Books, 2001.
Dekker 2001
Dekker 2005a
Dekker 2005b
Drewlo 2011
Egbor 2006
Empson 2005
Ferrazzi 1999
  • Ferrazzi E, Bulfamante G, Mezzopane R, Barbera A, Ghidini A, Pardi G. Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction. Placenta 1999;20(5-6):389-94.
Franco 2011
  • Franco C, Walker M, Robertson J, Fitzgerald B, Keating S, McLeod A, et al. Placental infarction and thrombophilia. Obstetrics and Gynecology 2011;117(4):929-34.
Fuke 1994
  • Fuke Y, Aono T, Imai S, Suehara N, Fujita T, Nakayama M. Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation. Gynecologic and Obstetric Investigation 1994;38(1):5-9.
Gates 2002
  • Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001689]
Greer 2006
Higgins 2008
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
Higgins 2011
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Kaandorp 2009
Khong 2004
  • Khong TY. Placental vascular development and neonatal outcome. Seminars in Neonatology 2004;9(4):255-63.
Kok 1998
Laws 2004
  • Laws PJ, Sullivan EA. Australia's mothers and babies, 2002. Sydney: Australian Institute of Health and Welfare, National Perinatal Statistics Unit, 2004.
McIntire 1999
Moe 1982
Rana 2012
  • Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, et al. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension 2012;60(2):451-8.
RevMan 2008
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Robson 2002
Roth 1999
  • Roth S, Chang TC, Robson S, Spencer JA, Wyatt JS, Stewart AL. The neurodevelopmental outcome of term infants with different intrauterine growth characteristics. Early Human Development 1999;55(1):39-50.
Sander 2005
  • Sander CM, Gilliland D, Richardson A, Foley KM, Fredericks J. Stillbirths with placental hemorrhagic endovasculitis: a morphologic assessment with clinical implications. Archives of Pathology and Laboratory Medicine 2005;129(5):632-8.
Sibai 2005
  • Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365(9461):785-99.
Sobel 2011
Tan 2005
Toal 2008
  • Toal M, Keating S, Machin G, Dodd J, Adamson SL, Windrim RC, et al. Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images. American Journal of Obstetrics and Gynecology 2008;198(3):330.e1-330.e7.
Viero 2004
  • Viero S, Chaddha V, Alkazaleh F, Simchen M, Malik A, Kelly E, et al. Prognostic value of placental ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries. Placenta 2004;25(8-9):735-41.
Walker 2003
  • Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD003580]
Walker 2012
  • Walker MG, Fitzgerald B, Keating S, Ray JG, Windrim R, Kingdom JC. Sex-specific basis of severe placental dysfunction leading to extreme preterm delivery. Placenta 2012;33(7):568-71.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Dodd 2010